Epeius Biotechnologies Corporation Gains Federal Support For Landmark Clinical Trials Of Tumor-Targeted Gene Therapy Using Rexin-G(TM) For Metastatic Cancer
SAN MARINO, Calif., Oct. 2 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that it received a prestigious R01 grant from the United States Food and Drug Administration (U.S. FDA) to assist in the evaluation of a Phase I/II clinical trial using Rexin-G(TM) for advanced or metastatic pancreatic cancer. The ongoing clinical study, centered at the Mayo Clinic in Rochester, Minnesota, will examine the safety and potential efficacy of repeated intravenous infusions of Rexin-G, the world's first tumor-targeted gene delivery vehicle, in the treatment of intractable pancreatic cancer.
Rexin-G, the company's lead gene therapy product, has received Orphan Drug Status based on unprecedented demonstrations of single-agent efficacy in this deadly type of cancer, where so many biologic and chemotherapeutic agents have failed. Designed to function in the context of the human circulatory system, Rexin-G seeks out, accumulates in, and selectively delivers a tumor-killing designer gene to primary and metastatic cancers that have spread throughout the body. Rexin-G has recently been approved for the treatment of all solid tumors in the Philippines and is currently in clinical trials in the U.S. An article in this month's issue of the International Journal of Oncology, provides definitive evidence that "Rexin-G is a highly-active agent against a broad spectrum of chemo-resistant tumor types."
Emerging from a start-up biopharmaceutical company into a global leader in genetic medicine, Epeius Biotechnologies is concurrently undertaking a series of pioneering international studies to expand the scope of its clinical applications.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer-gene therapy, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced GMP and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. To learn more about Rexin-G(TM) and Epeius' pipeline of proprietary compounds currently available for partnership, please visit us at http://www.epeiusbiotech.com.
Epeius Biotechnologies CorporationCONTACT: Amy Blackley, Ph.D., Porter Novelli Life Sciences,+1-619-849-6008, ablackley@pnlifesciences.com, for Epeius BiotechnologiesCorporation
Web site: http://www.epeiusbiotech.com/